18
3
9
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7832 |
Ibrolipim
NO-1886 |
LPL Receptor | GPCR/G Protein |
Ibrolipim (NO-1886) 是口服具有活力的脂蛋白脂肪酶 (LPL) 激活剂。它能够降低血浆甘油三酸酯,增加高密度脂蛋白胆固醇水平,具有肾保护和降血脂的作用。 | |||
T3625 |
Bempedoic acid
ETC1002,ESP-55016,ETC 1002,ETC-1002 |
ATP Citrate Lyase; AMPK | Chromatin/Epigenetic; Metabolism; PI3K/Akt/mTOR signaling |
Bempedoic acid (ETC1002) 是一种 ATP-柠檬酸裂解酶抑制剂,可激活AMPK。它是脂质和碳水化合物代谢的调节剂。 | |||
T4058 |
R-IMPP
|
Others; Serine/threonin kinase | Cell Cycle/Checkpoint; Metabolism; Others |
R-IMPP 是抗 PCSK9分泌的药物 (IC50=4.8 μM),靶向作用于 80S 核糖体,抑制 PCSK9 蛋白的翻译。 | |||
T9916 |
Alirocumab
|
Others | Others |
Alirocumab 是 PCSK9的人单克隆抗体。它能够特异性结合肝脏低密度脂蛋白 (LDL) 受体的下调剂 PCSK9,增强肝脏结合 LDL-胆固醇 (LDL-C) 的能力,降低血液中的 LDL-C 水平。它可用于研究高胆固醇血症。 | |||
T76739 |
Bococizumab
RN316,PF-04950615 |
Others | Others |
Bococizumab(PF-04950615) 是一种针对PCSK9的人源化mAb,也是一种在肝脏中合成PCSK9的抑制剂,可降低低密度脂蛋白胆固醇 (LDL-C) 在血液中的含量。Bococizumab 可用于治疗高胆固醇血症。 | |||
T7072 |
Pitavastatin
|
Others | Others |
Pitavastatin (NK-104) 是有效的羟甲基戊二酰-CoA(HMG-CoA)还原酶抑制剂。Pitavastatin 抑制乙酸合成胆固醇,在 HepG2 细胞中的IC50为 5.8 nM。Pitavastatin 是一种高效的肝细胞低密度脂蛋白胆固醇 (LDL-C) 受体诱导剂。Pitavastatin 具有抗动脉粥样硬化、抗哮喘、抗骨关节炎、抗肿瘤、神经保护、肝保护和肾保护等作用。 | |||
T76974 |
Tafolecimab
|
||
Tafolecimab (IBI-306) 是一种人源 lgG2 单克隆抗体,可特异性结合 PCSK-9并通过抑制 PCSK-9 介导的低密度脂蛋白受体的内吞作用降低 LDL-C 水平,进而增强对 LDL-C 的清除,导致 LDL-C 水平降低。Tafolecimab 可用于高胆固醇血症的研究。 | |||
T68695 |
(R)-Bambuterol
|
Others | Others |
Bambuterol is a prodrug of β2-agonist commonly used for the treatment of asthma and chronic obstructive pulmonary disease (COPD) with the advantage of once daily dosing and favorable side effect profile. Administration of a single-dose of R-bambuterol resulted in dose-dependent reductions in the levels of plasma LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1) at Tmax. R-bambuterol can lower the plasma levels of LD... | |||
T11386 |
Gemcabene calcium
PD-72953 calcium |
Others | Others |
Gemcabene calcium , a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) andexerting anti-inflammatory activity, lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP). | |||
T60646 |
PCSK9 modulator-3
|
Others | Others |
PCSK9 modulator-3 (Compound 13) 是PCSK9的有效调节剂,EC50值为 2.46 nM,在高脂血症研究中具有潜力。PCSK9 是已证实的降低低密度脂蛋白胆固醇 (LDL-C) 的靶点。 | |||
T60764 |
PCSK9 modulator-4
|
Others | Others |
PCSK9 modulator-4 (Compound 21) 是可以用于高血脂研究的,PCSK9的有效调节剂 (EC 50 = 0.15 nM)。PCSK9 是得到验证的一种降低低密度脂蛋白胆固醇 (LDL-C) 的靶标。 | |||
T60541 |
PCSK9 modulator-2
|
Others | Others |
PCSK9 modulator-2 (Compound 1) 是一种有效的PCSK9调节剂(EC50 = 202 nM), 具有用于高脂血症的研究潜力。PCSK9 是降低低密度脂蛋白胆固醇 (LDL-C) 的靶点。 | |||
T79051 |
PCSK9-IN-15
|
Others | Others |
PCSK9-IN-15(化合物5)是一种高效PCSK9抑制剂,亲和力强(KD<200 nM)。该化合物与胆固醇代谢相关,可调控低密度脂蛋白胆固醇(LDL-C)水平,适用于研究降低胆固醇及血脂异常。 | |||
T62380 |
20-HC-Me-Pyrrolidine
|
Others | Others |
20-HC-Me-Pyrrolidine 是一种有效的 Aster 蛋白抑制剂,对 Aster-A、Aster-B 和 Aster-C 具有抑制作用, IC50 分别为 0.11 μM、0.06 μM 和 0.71 μM。20-HC-Me-Pyrrolidine 阻止 Aster 蛋白结合和转移胆固醇,抑制低密度脂蛋白 (LDL) 胆固醇向内质网 (ER) 的移动。 | |||
T62052 |
AMPK activator 6
|
Others | Others |
AMPK activator 6 (Compound GC) 可降低 HepG2 和 3T3-L1 细胞中的脂质含量并激活AMPK 通路。AMPK activator 6 对血清中甘油三酯 (TG)、总胆固醇 (TC)、低密度脂蛋白-C (LDL-C) 和其他生化指标的增加有显著的抑制作用。AMPK activator 6 在非酒精性脂肪肝(NAFLD)和代谢综合征中有研究价值。 | |||
T62598 |
Pitavastatin sodium
|
Others | Others |
Pitavastatin (NK-104) sodium 是一种有效的羟甲基戊二酰-CoA(HMG-CoA) 还原酶抑制剂,也是一种高效的肝细胞低密度脂蛋白胆固醇 (LDL-C) 受体诱导剂。Pitavastatin sodium 在 HepG2 细胞中,能够抑制乙酸合成胆固醇 (IC50: 5.8 nM) 。Pitavastatin sodium 表现出抗动脉粥样硬化、抗哮喘、抗骨关节炎、神经保护、抗肿瘤、肝保护和肾保护作用。 | |||
T35463 |
(±)14(15)-EET
(±)14,15-EET,(±)14,15-EpETrE,(±)14(15)-EET |
Others | Others |
(±)14(15)-EET is a metabolite of arachidonic acid that is formed via epoxidation of arachidonic acid by cytochrome P450.[1],[2] It prevents increases in leukotriene B4, ICAM-1, and chemokine (C-C motif) ligand 1 (CCL2) induced by oxidized LDL in primary rat pulmonary artery endothelial cells (RPAECs) when used at a concentration of 1 μM.[3] (±)14(15)-EET induces dilation of preconstricted isolated canine coronary arterioles (EC50 = 0.2 pM).[4] It reduces myocardial infarct size as a percentage o... | |||
T63430 |
Rosuvastatin Sodium
|
Others | Others |
Rosuvastatin Sodium 是竞争性HMG-CoA 还原酶 (HMGCR) 抑制剂 (IC50: 11 nM),能够有效阻断hERG 电流 (IC50: 195 nM)。Rosuvastatin Sodium 可以有效减少低密度脂蛋白 (LDL) 胆固醇,甘油三酯和 C- 反应蛋白水平。Rosuvastatin Sodium 能够减少成熟 hERG 的表达,并抑制及热休克蛋白 70 (Hsp70) 与 hERG 蛋白的相互作用。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3771 |
Methyl protodioscin
山药,Smilax saponin B,NSC-698790 |
Apoptosis | Apoptosis |
Methyl protodioscin (Smilax saponin B) 是一种甾二糖苷,能诱导细胞周期阻滞,具有抗肿瘤活性。 | |||
T3427 |
Polydatin
Piceid,虎杖苷,Polydotin Peceid |
Apoptosis; Mitophagy; NF-κB; Autophagy | Apoptosis; Autophagy; NF-κB |
Polydatin (Piceid) 是从传统中药虎杖根中提取的一种天然产物,在多个实验模型中具有抗炎作用。它可抑制 G6PD,并诱导氧化和内质网应激。 | |||
TN3675 |
Cleomiscosin C
|
LDL | Metabolism |
Cleomiscosin C has antioxidant activity, it protects against the oxidative modification of apoB-100 induced by either Cu2+ or HOCl ( IC50s of 23.6 and 3.9 microM, respectively), suggests that it could be beneficial in preventing LDL oxidation in atheroscl |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01297 |
LDLR Protein, Cynomolgus, Recombinant (His)
LDLR,LDL R,LDL receptor,... |
Cynomolgus | HEK293 Cells |
The low density lipoprotein receptor (LDLR) is the founding member of the LDL R family of widely expressed cell surface scavenger receptors. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. LDLR Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 86 kDa and the accession number is XP_005588053.1. | |||
TMPH-00947 |
APOC2 Protein, Human, Recombinant (His & SUMO)
ApoC-II,APC2,Apolipoprotein C-II,... |
Human | E. coli |
Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. Both proapolipoprotein C-II and apolipoprotein C-II can activate lipoprotein lipase. In normolipidemic individuals, it is mainly distributed in the HDL, whereas in hypertriglyceridemic individuals, predominantly found in the VLDL and LDL. APOC2 Protein, Human, Recomb... | |||
TMPK-00402 |
LDLR Protein, Human, Recombinant (His & Avi)
FH,LDLCQ2,LDL R,LDLR,FH<... |
Human | HEK293 Cells |
The low density lipoprotein receptor (LDLR) is the founding member of the LDL R family of widely expressed cell surface scavenger receptors. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. LDLR Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 87.6 kDa and the accession number is P01130-1. | |||
TMPH-02502 |
LRPAP1 Protein, Mouse, Recombinant (His & Myc)
Heparin-binding protein 44,Alpha-2-macroglobulin re... |
Mouse | Baculovirus Insect Cells |
Molecular chaperone for LDL receptor-related proteins that may regulate their ligand binding activity along the secretory pathway. LRPAP1 Protein, Mouse, Recombinant (His & Myc) is expressed in Baculovirus insect cells with N-10xHis and C-Myc tag. The predicted molecular weight is 18.2 kDa and the accession number is P55302. | |||
TMPJ-00014 |
Resistin Protein, Human, Recombinant (His)
Resistin,C/EBP-epsilon-regulated myeloid-spec |
Human | E. coli |
Resistin known as adipose tissue-specific secretory factor (ADSF) or C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein (XCP1) that seems to suppress insulin ability to stimulate glucose uptake into adipose cells. The length of the resistin pre-peptide in human is 108 amino acid residues and in the mouse and rat it is 114 aa; the molecular weight is ~12.5 kDa. Resistin is a cytokine whose physiologic role has been the subject of much controversy regarding its involvement wit... | |||
TMPY-02128 |
Serpin B1 Protein, Human, Recombinant (His)
HEL57,serpin peptidase inhibitor, clade B (ovalbumi... |
Human | Baculovirus Insect Cells |
SerpinB1 is an endogenous inhibitor of serine proteases recognized for its anti-inflammatory and host-protective properties. Serum SerpinB1 levels are elevated in patients with type 2 diabetes compared with that in healthy subjects and are negatively correlated with serum LDL-C. serpinB1 as an endogenous protein that can potentially be harnessed to enhance functional beta cell mass in patients with diabetes. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TMIH-0109 |
Bempedoic acid-d4
|
||
Bempedoic acid-d4 是 Bempedoic acid 的氘代化合物。Bempedoic acid 的 CAS 号为 738606-46-7。ETC-1002 是一种 ATP-柠檬酸裂解酶抑制剂,可激活AMPK。它是脂质和碳水化合物代谢的调节剂。 | |||
T71306 |
Gemfibrozil-d6
|
||
Gemfibrozil-d6 is intended for use as an internal standard for the quantification of gemfibrozil by GC- or LC-MS. Gemfibrozil is a peroxisome proliferator-activated reporter α and PPARγ agonist. In vivo, gemfibrozil reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia. Gemfibrozil reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C) motif l... | |||
TMIJ-0119 |
Pitavastatin-d4 Sodium Salt
|
||
Pitavastatin-d4 Sodium Salt 是 Pitavastatin Sodium Salt 的氘代化合物。Pitavastatin Sodium Salt 的 CAS 号为 574705-92-3。 |